NCT04369794View on ClinicalTrials.gov

COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement

PHASE4CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

June 4, 2022

Study Completion Date

August 2, 2023

Conditions
COVID-19Therapeutic VaccineBCGSARS-CoV 2Transmission
Interventions
BIOLOGICAL

BCG

0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose

BIOLOGICAL

Placebo

0.9% saline in the same volume as the BCG vaccine in a single dose

Trial Locations (1)

13083-887

Hospital das Clínicas Unicamp, Campinas

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Paulínia Municipal Hospital

UNKNOWN

lead

University of Campinas, Brazil

OTHER

NCT04369794 - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement | Biotech Hunter | Biotech Hunter